Table 1. Expression level of genes induced at least 2 fold at 8 hours in AP20187 treated Fv2E‐PERK and 1.5 fold in tunicamycin treated wildtype (WT) cells. The expression level of the same genes in AP20187‐treated Fv2E‐PERK expressing mutant eIF2αA/A cells and tunicamycin‐treated Perk−/− cells is shown for comparison. The genes have been grouped into functional categories six of which are shown here. (A complete list of all 506 genes activated at least two fold by AP20187 treatment is provided in a supplementary table). The mean±the average deviation of the expression level (normalized signal strength, see methods) in untreated and treated cells from two independent experiments is shown
eIF2α (S/S) Fv2E‐PERK)eIF2α (A/A) Fv2E‐PERKPerk+/+Perk−/−
AP20187AP20187TunicamycinTunicamycin
NameDescriptionGenbank0 hr4 hr8 hr0 hr4 hr8 hr0 hr6 hr0 hr6 hr
Translation/amino acid transport and metabolism
 Myd116eIF2alpha phosphatase, mouse GADD34X518291.70±0.289.19±0.3512.97±0.821.05±0.090.93±0.201.06±0.070.06±0.296.90±0.130.45±0.100.71±0.38
 Abcf2ATP‐binding cassette, sub‐family F2, (GCN20)AI8373183.97±0.874.30±0.488.13±1.151.64±0.011.70±0.211.62±0.230.09±0.581.04±0.040.59±0.260.12±0.09
 Asnsasparagine synthetaseAV2539080.86±0.153.90±0.607.91±1.951.11±0.070.80±0.010.94±0.021.08±0.352.07±0.050.52±0.041.29±0.42
 Mthfr5,10‐methylenetetrahydrofolate reductaseAW2142251.25±0.209.84±0.947.78±0.381.16±0.021.44±0.160.91±0.260.68±0.261.51±0.300.41±0.250.97±0.57
 Slc1a4glutamate/neutral amino acids transporterU752151.96±0.065.92±0.266.51±0.690.97±0.021.32±0.051.03±0.010.96±0.152.23±0.710.16±0.090.59±0.40
 Sars1seryl‐aminoacyl‐tRNA synthetase 1AI8373952.24±0.843.28±0.426.13±1.071.37±0.021.21±0.131.15±0.270.20±0.291.80±0.310.33±0.060.97±0.32
 Carscysteinyl‐tRNA synthetaseAI8487321.26±0.375.21±0.256.07±0.891.11±0.111.33±0.071.02±0.090.79±0.261.95±0.100.05±0.200.54±0.50
 SYTCthreonyl‐tRNA synthetaseAI8496201.66±0.183.15±0.004.74±0.571.04±0.201.10±0.060.97±0.020.80±0.201.44±0.020.58±0.090.78±0.34
 Rps6ka2ribosomal protein S6 kinase, 90kD, polypeptide 2AJ1310211.75±0.243.65±0.254.72±1.010.90±0.140.92±0.140.74±0.350.67±0.291.80±0.310.79±0.010.92±0.23
 Larsleucyl‐tRNA synthetaseAI8440891.26±0.172.35±0.014.45±0.621.19±0.051.19±0.011.10±0.020.96±0.141.89±0.120.63±0.030.92±0.03
 Eprsglutamyl‐prolyl‐tRNA synthetaseX543271.73±0.342.28±0.314.39±0.351.08±0.071.18±0.121.32±0.070.99±0.201.71±0.270.52±0.040.76±0.04
 Pycspyrroline‐5‐carboxylate synthetaseAW1248891.86±0.593.15±0.074.32±0.091.05±0.081.04±0.050.93±0.060.76±0.182.08±0.140.56±0.090.93±0.23
 Narsasparaginyl‐tRNA synthetaseAW1258741.76±0.272.63±0.044.21±0.861.50±0.071.44±0.041.12±0.180.95±0.271.64±0.220.64±0.060.83±0.02
 WRSalpha‐2 subunit; tryptophanyl‐tRNA synthetaseX696562.00±0.262.39±0.174.06±0.651.05±0.061.10±0.060.98±0.020.73±0.393.06±0.300.30±0.080.29±0.10
 Aarsalanyl‐tRNA synthetaseAI8393921.73±0.363.13±0.154.01±0.321.06±0.061.05±0.120.86±0.140.67±0.051.52±0.060.60±0.121.00±0.12
 Eif4ebp1eIF4E binding protein 1U286561.66±0.482.80±0.233.82±0.561.02±0.011.02±0.000.86±0.170.77±0.141.55±0.190.49±0.120.87±0.33
 ESTphosphoserine phosphatase homologueAI8465451.34±0.222.54±0.233.74±0.371.30±0.121.21±0.091.12±0.320.87±0.171.57±0.040.54±0.070.96±0.06
 Yarstyrosyl‐tRNA synthetaseAW1225421.33±0.562.85±0.243.59±0.241.11±0.171.14±0.131.03±0.040.96±0.061.59±0.150.85±0.111.08±0.12
 Elp3elongation protein 3 homolog (S. cerevisiae)AI8512291.45±0.161.47±0.282.91±0.061.00±0.041.16±0.041.06±0.030.26±0.111.04±0.030.70±0.020.47±0.01
 ESTisoleucyl‐tRNA synthetaseAI8483931.23±0.152.30±0.052.79±0.270.82±0.100.85±0.140.75±0.100.78±0.111.23±0.070.68±0.031.00±0.03
 Slc1a7neutral amino acid transporter, ASCT2L421151.16±0.271.78±0.422.39±0.201.08±0.241.11±0.051.17±0.050.72±0.361.45±0.000.11±0.830.24±0.55
 Shmt2serine hydroxymethyl transferase 2AV0099781.02±0.011.47±0.012.34±0.450.78±0.070.86±0.140.86±0.060.70±0.341.67±0.480.42±0.030.80±0.77
 ESTUVRAG homologue, UV radiation resistanceAI02025921.66±5.8964.05±9.2649.58±14.94.35±0.054.89±0.174.08±0.770.01±0.000.07±0.370.10±0.630.01±0.00
 GchGTP cyclohydrolase 1L097372.98±1.0512.96±1.1521.76±0.800.88±0.160.68±0.020.63±0.360.62±0.063.24±0.910.93±0.150.47±0.52
 GADD45Mus musculus GADD45 protein (gadd45) geneU009372.74±0.0621.42±0.4220.24±0.341.11±0.101.27±0.100.92±0.000.65±0.5510.25±1.160.24±0.060.44±0.40
 Ndr1N‐myc downstream regulated 1U605935.76±1.829.26±0.7014.09±2.251.02±0.241.01±0.351.05±0.350.67±0.112.94±0.550.59±0.040.85±0.47
 Sqstm1sequestosome 1; A170, STAPU409301.97±0.984.31±0.656.11±0.591.21±0.041.26±0.291.26±0.010.56±0.171.74±0.080.31±0.350.65±0.43
 Arnt3aryl hydrocarbon receptor nuclear translocator‐likeAB0144941.18±0.083.08±0.213.04±0.030.95±0.091.06±0.080.80±0.230.35±0.031.10±0.100.56±0.110.54±0.04
 Dnajb9DnaJ (Hsp40) homolog, subfamily B, member 9AI8356301.00±0.031.86±0.102.90±0.020.88±0.190.91±0.220.78±0.560.69±0.263.74±0.280.17±0.050.58±0.09
 Tbcetubulin‐specific chaperone eAI8521611.25±0.023.40±0.032.82±0.341.44±0.011.45±0.170.98±0.310.70±0.131.08±0.060.41±0.500.57±0.45
 Clcn3chloride channel 3AF0293470.77±0.131.55±0.701.96±0.260.98±0.131.20±0.090.86±0.030.09±0.571.69±0.061.04±0.341.67±0.03
 Dnajc3DnaJ (Hsp40) homolog, subfamily C, member 3, p58U284230.28±0.030.80±0.001.06±0.180.77±0.240.85±0.390.76±0.051.24±0.276.50±1.690.52±0.001.24±0.07
 Pon2paraoxonase 2; esterase; anti‐lipid oxidationL485148.21±0.5412.74±1.7717.43±1.802.62±0.312.973±0.092.180±0.670.09±0.520.09±0.551.06±0.921.67±0.78
 B5R.1NADH‐cytochrome B5 reductaseAI8396902.80±0.174.60±0.2610.00±1.511.06±0.001.135±0.180.924±0.400.98±0.273.15±0.330.44±0.010.57±0.18
 ESTthioredoxin‐like protein HT014 homologueAA7983651.33±0.133.23±0.003.16±0.341.90±0.031.894±0.291.196±0.510.37±0.070.75±0.350.73±0.280.60±0.36
 Txnipthioredoxin interacting proteinAI8391380.88±0.232.17±0.052.28±0.251.08±0.031.307±0.100.879±0.310.64±0.431.43±0.260.40±0.050.51±0.40
 Cpocoproporphyrinogen oxidaseD163330.78±0.051.64±0.021.83±0.020.88±0.361.063±0.020.929±0.180.95±0.443.31±0.340.42±0.021.00±0.11
 Siah2seven in absentia 2; ubiquitin ligaseZ195811.19±0.083.52±0.093.45±0.500.88±0.010.937±0.090.952±0.050.80±0.022.63±0.330.89±0.100.41±0.49
 Fbxo8f‐box only protein 8AI8449320.97±0.452.34±0.622.92±0.332.38±0.581.828±0.291.182±0.260.69±0.341.17±0.220.65±0.011.15±0.09
 Ctsccathepsin CU746831.06±0.231.10±0.012.24±0.100.33±0.120.295±0.050.136±0.090.53±1.150.84±0.920.32±0.200.31±0.57
 Wfs1Wolfram syndrome 1 homolog, ER localizedAF0844822.71±0.423.45±0.157.75±0.511.12±0.231.185±0.240.990±0.260.06±0.275.64±0.090.04±0.090.73±0.05
 Spaftransitional endoplasmic reticulum ATPaseAF0165442.00±0.283.12±0.064.74±0.511.00±0.020.877±0.110.728±0.130.27±0.160.90±0.320.65±0.180.34±0.25
 Herpud1homocysteine‐inducible‐ubiquitin‐like domain 1AI8469381.07±0.154.28±0.193.11±0.170.94±0.070.898±0.140.686±0.170.38±0.333.84±0.330.19±0.070.74±0.17
 Ero1lendoplasmic reticulum oxidoreductin 1‐likeAA7986241.00±0.141.91±0.262.59±0.330.92±0.101.065±0.081.066±0.230.52±0.472.03±0.020.72±0.211.13±0.12
 Sel1hSel1 (suppressor of lin‐12) 1 homologueAW1218400.79±0.431.04±0.302.19±0.731.04±0.010.887±0.111.029±0.120.77±0.565.96±4.700.20±0.040.35±0.12
 ERO1Lbendoplasmic reticulum oxidoreductin 1‐like‐betaAI0491440.27±0.040.81±0.151.09±0.020.77±0.080.823±0.050.599±0.100.89±0.264.02±0.570.68±0.161.44±0.54
 Atf3activating transcription factor 3U191182.54±0.2624.52±1.6215.21±1.690.92±0.101.041±0.180.881±0.080.73±0.083.35±0.570.64±0.280.94±0.14
 Nrbf1nuclear receptor binding factor 1AW0464834.30±0.564.74±0.558.75±0.112.41±0.262.378±0.241.855±0.870.03±0.061.68±1.710.11±0.800.06±0.28
 Nfkb2nuclear factor of kappa B cell 2AW0478993.27±0.236.45±0.328.26±1.040.99±0.010.971±0.131.043±0.080.38±0.090.80±00.94±0.110.86±0.15
 Atf5activating transcription factor 5AB0122762.22±0.275.79±0.267.54±2.441.36±0.041.365±0.331.050±0.130.99±0.212.80±0.560.23±0.120.37±0.35
 Chop‐10transcription factor CHOP, GADD153X670830.98±0.084.35±0.656.41±0.251.10±0.271.176±0.150.940±0.190.60±0.3411.30±0.070.49±0.050.75±0.27
 Nupr1nuclear protein 1AI8526411.36±0.235.85±0.476.29±1.641.26±0.171.449±0.321.119±0.161.22±0.753.37±0.390.02±0.010.59±0.25
 CebpgCCAAT/enhancer binding protein (C/EBP), gammaAB0122731.94±0.226.31±0.395.96±0.121.07±0.031.068±0.010.906±0.070.89±0.251.75±0.090.52±0.290.60±0.19
 Relb(v‐rel) oncogene related BM833802.60±0.029.02±0.605.87±1.420.90±0.071.054±0.091.182±0.270.56±0.211.00±0.410.68±0.090.68±0.00
 Tbpl1TATA box binding protein‐like 1AB0176971.79±0.173.42±0.115.63±0.451.89±0.272.069±0.051.415±0.530.55±0.471.08±0.080.55±0.200.54±0.13
 CebpbCCAAT/enhancer binding protein (C/EBP), betaM610072.10±0.373.31±0.414.23±0.681.02±0.030.952±0.071.099±0.300.98±0.301.96±0.050.48±0.020.55±0.13
 Cbx4chromobox homolog 4, transcriptional repressorU633871.48±0.373.07±0.084.16±0.881.17±0.031.111±0.231.107±0.100.91±0.101.98±0.410.61±0.190.91±0.01
 SKiPSki‐interacting protein, nuclear receptor coactivatorAW0466711.91±0.602.84±0.233.87±0.091.16±0.011.319±0.280.973±0.130.55±0.221.15±0.200.75±0.110.65±0.17
 ATF6ATF6 alpha homologueAA5920691.32±0.302.05±0.243.85±0.810.83±0.390.979±0.151.059±0.140.30±0.141.86±0.010.48±0.070.30±0.08
 Atf4activating transcription factor 4M940871.62±0.133.01±0.183.60±0.610.85±0.081.012±0.021.045±0.060.84±0.021.80±0.020.52±0.150.99±0.19
 Nfil3; E4BP4NFIL3/E4BP4 transcription factorU831481.51±0.134.29±0.493.56±0.370.87±0.160.927±0.190.756±0.310.60±0.091.92±0.080.28±0.030.29±0.01
 Lmo4LIM only 4; transcriptional regulator cofactorAF0746000.94±0.272.98±0.063.47±0.151.16±0.321.108±0.210.976±0.200.41±0.071.18±0.540.24±0.240.31±0.06
 Klf4Kruppel‐like factor 4 (gut)U203441.17±0.023.58±0.032.74±0.020.97±0.011.070±0.070.770±0.080.85±0.431.82±0.550.24±0.330.35±0.49
 Xbp1X‐box binding protein 1AW1238801.00±0.062.64±0.322.65±0.291.07±0.060.950±0.030.735±0.190.63±0.141.14±0.120.12±0.010.36±0.00
 Ets2E26 avian leukemia oncogene 2, 3′ domainJ041031.22±0.382.17±0.282.41±0.381.00±0.061.028±0.220.881±0.100.66±0.041.49±0.170.37±0.180.28±0.01
 Rxrip110retinoid X receptor interacting protein 110U220150.68±0.121.52±0.071.74±0.491.01±0.011.013±0.010.888±0.110.53±0.181.19±0.100.97±0.101.17±0.71
  • Genes induced at least 2 fold at 8 hours in AP20187 treated Fv2E‐PERK and 1.5 fold in tunicamycin treated wildtype (WT) cells. The genes have been grouped into functional categories six of which are shown here. (A complete list of all 506 genes activated at least two fold by AP20187 treatment is provided in a supplementary tables 1 and 2). The mean±the average deviation of the expression level (normalized signal strength, see methods) in untreated and treated cells from two independent experiments is shown.